Nuvectis Pharma (Nuvectis Pharma) EBIT : $-23.19 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma EBIT?

Nuvectis Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-4.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.19 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nuvectis Pharma's annualized ROC % for the quarter that ended in Mar. 2024 was -485.41%. Nuvectis Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nuvectis Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -23.93%.

Nuvectis Pharma EBIT Historical Data

The historical data trend for Nuvectis Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma EBIT Chart

Nuvectis Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-12.89

-19.23

-22.90

Nuvectis Pharma Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial								-4.10	-5.77	-6.16	-6.87	-4.40

Competitive Comparison of Nuvectis Pharma's EBIT

For the Biotechnology subindustry, Nuvectis Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvectis Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's EV-to-EBIT falls into.

Nuvectis Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.19 Mil.

Nuvectis Pharma (NAS:NVCT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nuvectis Pharma's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-17.584 * ( 1 - 0% )	/	( (3.798	+	3.447)	/ 2 )
=	-17.584	/	3.6225
=	-485.41 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.185	-	3.186	-	( 19.126	-	max(0, 6.984	-	19.185	+	19.126	))
=	3.798

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.714	-	2.245	-	( 19.464	-	max(0, 5.692	-	19.714	+	19.464	))
=	3.447

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nuvectis Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-17.584	/	( ( (0 + max(-6.925, 0))	+	(0 + max(-5.442, 0)) )	/	2 )
=	-17.584	/	( ( 0	+	0 )	/	2 )
=	-17.584	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.058999999999997)	-	(3.186	+	0	+	3.798)
=	-6.925

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.25)	-	(2.245	+	0	+	3.447)
=	-5.442

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nuvectis Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-23.192	/	96.913
	=	-23.93 %

Nuvectis Pharma EBIT Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvectis Pharma (Nuvectis Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024

Website

https://www.nuvectis.com

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.

Executives

Ron Bentsur	director, officer: Chairman & CEO	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri	10 percent owner	27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu	officer: Chief Science and Business Off	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh	officer: Chief Development Officer	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson	officer: Vice President, Finance	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Int. Principal Financial Off.	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan	director	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024